Plasma exchange for severe autoimmune hepatitis
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This study compares a blood-filtering treatment called therapeutic plasma exchange with standard medicines for people with severe autoimmune hepatitis. It aims to see if plasma exchange can improve outcomes when a liver transplant is not available soon.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have been diagnosed with autoimmune hepatitis using a score of at least 6 on a standard test
- Your liver disease is severe, with a MELD score above 24
- You cannot have a liver transplant within the next 28 days
- You do not have an active infection, active bleeding, or unstable blood pressure or heart rate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines, azathioprine and mycophenolate mofetil, to see which works better for treating autoimmune hepatitis. If you haven't been treated before, this trial could help find a more effective way to manage your condition.
This study looks at what factors affect how well the liver responds to treatment in people with autoimmune hepatitis. It may help doctors understand why some people respond better than others and could lead to more personalized care.
This trial tests whether a treatment called plasma exchange (which removes harmful substances from your blood and replaces them with healthy plasma) can help improve the function of other organs, like the kidneys or lungs, in people with advanced liver failure. It aims to find out if this treatment helps you recover better and to identify markers that show if the treatment is working.
This trial tests whether a treatment called plasmapheresis (plasma exchange) can help people with severe liver damage caused by medications when they also have chronic liver disease. The treatment filters the blood to remove harmful substances, which may improve liver function and recovery.
This trial tests whether a higher volume of plasma exchange (cleaning the blood to remove toxins) works better than the standard amount for children with acute liver failure who are not improving with usual care.
This study compares giving a higher versus a standard amount of plasma exchange, a treatment that cleans your blood, to see if it helps people with sudden liver failure and brain swelling. It aims to find out if a higher dose can better reduce brain pressure and improve outcomes.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.